Pfizer Inc (PFE)
19 Aug 2019
Eli Lilly and Company won a federal appeals court decision on Friday that protects its chemotherapy drug Alimta from generic competition from Pfizer Inc and Dr Reddy's Laboratories Ltd.
FRANKFURT Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations thanks to strong sales growth at its lab supplies unit and milestone payments from drug development partners.
* Life Science unit boosted by demand for lab supplies and gear
FRANKFURT, Aug 8 Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations, driven by drug development milestone payments from partners Pfizer and GlaxoSmithKline .
Pfizer Inc is urging the National Labor Relations Board to rule that a U.S. Supreme Court decision that said class-action waivers in employee arbitration agreements do not violate workers' rights to organize also applies to confidentiality clauses in the pacts.
NEW YORK, July 29 Shares of Mylan NV surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc's off-patent branded drugs business. But in the bigger picture, the surge is lost in a bleaker landscape for Mylan's stock price and the broader generic drug industry since 2015.
July 30 The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
WASHINGTON, July 29 The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.
Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.
July 29 Mylan NV's planned merger with Pfizer Inc's off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.